ModifiedUnitedHealthcarePolicy MMP372.12

Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease

Defines UnitedHealthcare Medicare Advantage coverage criteria, coding, and clinical context for noninvasive FFR derived from coronary CT angiography (FFR-ct) for evaluation of coronary artery disease in clinically stable symptomatic Medicare Advantage members.

Policy Summary

PayerUnitedHealthcare

PolicyNon-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease

Policy CodePolicy MMP372.12

Change TypeUpdated clinical evidence, FDA, and referencesarchived prior version

Effective DateMar 1, 2026

Next Review DateN/A

Key ActionPerform FFR-ct only after completion and interpretation of the base CCTA and document CCTA stenosis percentage (typically 40–90%) to support medical necessity.

SourceLink

POLICY UPDATE CHANGES

Updated Clinical Evidence, FDA, and References sections to reflect the most current information.

Updated list of documents available in the Medicare Coverage Database.

Archived previous policy version MMP372.11.

75580Primary CPT code listed for FFR-ct

Class IIAACC/AHA recommendation strength

1,400Patients in FORECAST trial

82.2%Pooled diagnostic accuracy

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for FFR-CT

Medical Necessity Criteria

Covered when ALL of the following are met

Primary coverage criteria: FFR-ct technology is FDA-approved and used to manage clinically stable symptomatic patients with coronary artery disease; it must be performed after completion and interpretation of a coronary CT angiography (CCTA) that demonstrates coronary artery stenosis of 40-90% in a proximal or mid coronary artery (or any 40-90% stenosis for patients with known CAD and persistent stable angina).stenosis 40-90%

CCTA must precede FFR-ct; applies to intermediate-risk patients as defined by guideline where indicated.

Clinical stability and urgency: The patient is clinically stable and does not have an unstable coronary syndrome or a clinical situation where urgent/timely evaluation is critical; FFR-ct is not appropriate for unstable presentations or when turnaround time could impact patient care.N/A

FFR-ct intended as alternative to stress testing; not for urgent/unstable care.

Exclusionary clinical circumstances: None of the following are present: prior prosthetic heart valves; prior coronary artery bypass grafts; intracoronary metallic stent; status post-heart transplantation; recent myocardial infarction within 30 days; prior pacemaker or defibrillator lead placement; newly diagnosed systolic heart failure without prior left heart catheterization; non-obstructing stenosis (<50%) on prior CTA or catheterization within 12 months without new symptoms; suspicion of acute coronary syndrome where MI/unstable angina have not been ruled out; or situations where turnaround times may impact prompt clinical care decisions.clinical exclusions listed

Presence of any listed circumstance makes FFR-ct not appropriate.

Use constraints: FFR-ct should not be used in conjunction with stress testing unless the CCTA quality is insufficient for FFR-ct; it is intended as an alternative to stress testing and should not be ordered if CCTA image quality is suboptimal or extensive plaque makes a high-quality CCTA unlikely.N/A

Avoid concurrent stress testing except when CCTA inadequate for FFR-ct.

ACC/AHA guideline-recommended indications

FFR-CT is recommended for diagnosis of vessel-specific ischemia and to guide revascularization decision-making in the following patient groups as per ACC/AHA guideline (Class IIA):

ACC/AHA recommended groups: Intermediate-risk patients with acute chest pain and previously unknown CAD with coronary stenosis of 40-90% in a proximal or mid coronary artery on CCTA; Intermediate-risk patients with stable chest pain and previously unknown CAD with coronary stenosis of 40-90% in a proximal or mid coronary artery on CCTA; Intermediate-risk patients with acute chest pain and known CAD with coronary stenosis of 40-90% in a proximal or mid coronary artery on CCTA; Patients with known nonobstructive CAD and stable chest pain with stenosis of 40-90% on CCTA.stenosis 40-90%

Guideline notes advantage of avoiding additional testing; do not order when CCTA image quality is suboptimal, extensive plaque is present, or delays in results could impact care.

FFR-ct is contraindicated when any of the following exclusionary clinical circumstances are present: prior placement of prosthetic valves, prior placement of grafts from coronary artery bypass graft (CABG) surgery, intracoronary metallic stent, status post-heart transplantation, recent myocardial infarction (≤30 days), prior pacemaker or defibrillator lead placement, or newly diagnosed systolic heart failure without prior left heart catheterization. Additionally, FFR-ct is not appropriate when there is a recent documentation of non-obstructing stenosis (<50%) on CTA or catheterization within the past 12 months without new symptoms, or when suspicion of acute coronary syndrome exists and MI/unstable angina have not been ruled out. Finally, FFR-ct should be avoided if turnaround times for results may impact prompt clinical care decisions.

FFR-CT should not be ordered when the coronary CT angiography (CCTA) image quality is suboptimal or when extensive atherosclerotic plaque makes acquisition of a high-quality CCTA unlikely. The ACC/AHA guideline additionally advises against FFR-CT when a delay in obtaining results could negatively affect patient care. In such situations consider alternative diagnostic strategies (for example, stress testing or proceeding to invasive evaluation) rather than relying on FFR-CT.

FFR-ct is not medically necessary if performed before the base CCTA has been completed and interpreted; CCTA interpretation must precede any FFR-ct request. FFR-ct is also not indicated when coronary stenoses are 40% (do not require confirmatory testing) or when stenoses are >strong>90% (patients with very high-grade stenosis should proceed directly to invasive catheterization). FFR-ct is intended as an alternative to stress testing and should not be used in conjunction with stress testing unless CCTA quality is insufficient for FFR-ct.

The evidence base for FFR-ct is limited by several factors: many reports are observational or registry-based rather than randomized controlled trials; potential conflicts of interest and author-related bias have been noted in systematic reviews; follow-up durations and outcome definitions vary across studies; and large-scale randomized trials remain limited. These constraints caution broad generalization of study findings and highlight the need for further independent randomized research to validate long-term clinical outcomes.

Coding and Billing

Covered CPT Codes (listed)CPTCovered

75580

Noninvasive estimate of coronary fractional flow reserve (FFR) derived from augmentative software analysis of the data set from a coronary computed tomography angiography, with interpretation and report by a physician or other qualified health care professional

Example Diagnosis CodesICD-10

R93.1

Abnormal findings on diagnostic imaging of heart and coronary circulation

Provider Actions, Authorization, and Documentation

Prior Authorization

Prior Authorization Required for CPT 75580

Prior authorization required for CPT 75580. Providers must obtain prior authorization before performing noninvasive FFR-CT (CPT 75580) when required by the member's Medicare Advantage benefit plan or applicable UnitedHealthcare prior authorization program.

Affected code: CPT 75580 — Noninvasive estimate of coronary fractional flow reserve (FFR) derived from augmentative software analysis of CCTA data, with interpretation and report.

Prior Authorization

Prior Authorization Delegation

For some UnitedHealthcare Medicare Advantage members, prior authorization and utilization management may be delegated to a contracted vendor or organization. When a delegate manages prior authorization for the member's plan, providers must follow the delegate's authorization requirements and processes for CPT 75580.

If a delegate manages utilization management/prior authorization for the member's Medicare Advantage plan, the delegate's requirements supersede the standard UHC process for that member.
Verify delegate identity and follow delegated submission channels and timelines.

Background and Clinical Context

Noninvasive fractional flow reserve derived from coronary CT angiography (FFR-ct) is a post-processing, computer-assisted analysis of previously acquired CCTA DICOM data that estimates lesion-specific changes in coronary blood pressure to assess the functional significance of stenoses. It is used to support clinicians evaluating clinically stable symptomatic patients with suspected or known coronary artery disease and can help determine whether invasive coronary angiography or revascularization is indicated when stenosis severity is uncertain.

Definitions

FFR-ct (definition)

DefinitionNoninvasive fractional flow reserve deduced from computed tomography (FFR-ct) is computer-assisted post-processing of coronary CT angiography (CCTA) DICOM data to estimate changes in intraluminal blood pressure and determine the functional significance of coronary stenoses.

PurposeProvides lesion-specific assessment of ischemia to support clinician decision-making in clinically stable symptomatic patients with suspected or known coronary artery disease.

Data sourceDerived from previously acquired CCTA images (post-processed software analysis), not from new invasive measurements.

Risk categories (guideline definitions)

Source guidelineDefinitions follow the 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain.

Intermediate-risk

Policy Summary

PayerUnitedHealthcare

PolicyNon-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease

Policy CodePolicy MMP372.12

Change TypeUpdated clinical evidence, FDA, and referencesarchived prior version

Effective DateMar 1, 2026

Next Review DateN/A

Key ActionPerform FFR-ct only after completion and interpretation of the base CCTA and document CCTA stenosis percentage (typically 40–90%) to support medical necessity.

SourceLink

On This Page

Note

Alternative to Stress Testing

FFR-CT is intended as an alternative to stress testing and should not be used in conjunction with stress testing unless the CCTA is of insufficient quality for FFR-CT and an alternative study is needed. Do not perform FFR-CT prior to completing and interpreting the base CCTA.

FFR-CT is an alternative to stress testing; ordering both concurrently is discouraged unless CCTA quality prevents FFR-CT.
FFR-CT must only be performed after the base CCTA has been completed and interpreted.

Documentation Required

Required Clinical Documentation and Recordkeeping

Providers must document clinical rationale and supporting imaging data when ordering and performing FFR-CT. Required documentation should be retained and made available upon request to support medical necessity and accurate claims submission.

Documentation must confirm completion and interpretation of the base CCTA, including percent stenosis and location (proximal or middle coronary artery) for lesions 40–90%.
Include clinical presentation (stable vs acute chest pain), risk stratification (intermediate risk as defined by relevant guidelines), troponin status if applicable, and prior coronary history.
Document any factors that would preclude FFR-CT (e.g., prior stent, grafts, valve prosthesis, recent MI) and turnaround-time considerations if delays could impact care.
Retain all imaging and report records to support claims and medical necessity; providers are responsible for accurate claims submission.

Denial Risk

Triggers for Noncoverage or Denial

FFR-CT is considered not medically necessary and may be denied when performed outside the stated clinical pathway or when imaging/timing limitations are present. Providers should avoid ordering FFR-CT in these circumstances to prevent claim denials.

Not medically necessary when FFR-CT is performed prior to completion and physician interpretation of the base CCTA.
Not medically necessary when coronary stenoses are >90% (proceed to catheterization) or <40% (low-grade stenosis not requiring confirmatory FFR-CT).
Not medically necessary when clinical circumstances listed in policy are present (e.g., prior intracoronary stent, prior CABG grafts, prior valve prosthesis, recent MI within 30 days, status post heart transplantation).
Claims may be denied if documentation is insufficient to support medical necessity or if records are not retained per instructions for use.

Denial Risk

Inappropriate Use Based on Imaging Quality or Timeliness

Do not order FFR-CT when the base CCTA is suboptimal or when extensive coronary plaque is present and a high-quality CCTA is unlikely. Also avoid ordering if expected turnaround times would delay prompt clinical decision-making.

Inappropriate when CCTA imaging quality is poor (motion artifact, inadequate contrast, etc.) or extensive calcified plaque limits accurate analysis.
Inappropriate when delays in obtaining FFR-CT results could negatively impact patient care decisions; consider alternative testing such as stress testing or invasive angiography.
FFR-CT is not appropriate for unstable coronary syndromes or when urgent evaluation is required.

Note

Testing Alternatives

Guidelines recommend FFR-CT or stress testing as alternative noninvasive strategies; no step-therapy (mandatory trial of stress testing before FFR-CT) is mandated by this policy, but FFR-CT should be used consistent with guideline indications and CCTA findings.

Recommended alternatives: stress testing (functional testing) or invasive angiography as clinically indicated.
No requirement for step-therapy forcing stress testing prior to FFR-CT; clinical judgment and guideline-consistent pathways should guide choice of noninvasive strategy.

Patients classified as intermediate risk per the 2021 guideline — referenced for use of FFR-CT when CCTA shows 40–90% stenosis in proximal or mid coronary arteries.

High-riskHigh-risk terminology aligns with the 2021 guideline definitions and is used to exclude patients with unstable presentations (e.g., suspected acute coronary syndrome) from FFR-CT evaluation.

FFR-CT / FFRct (definition & use)

TermFFR-CT / FFRct — computed-tomography derived fractional flow reserve used to diagnose vessel-specific ischemia and to guide revascularization decisions based on CCTA data.

Clinical roleRecommended as an alternative to stress testing within guideline clinical pathways for patients with 40–90% stenosis on CCTA to avoid additional testing and inform revascularization decisions.

LimitationsShould not be ordered when CCTA image quality is suboptimal, when extensive plaque makes high-quality CCTA unlikely, or when delays in results could impact care.

HeartFlow FFRct (commercial service)

ProductHeartFlow FFRct — a commercially available FFRct service referenced by NICE guidance.

Diagnostic performanceNICE states HeartFlow FFRct is safe and has a high level of diagnostic accuracy when used appropriately.

Technical requirementRequires access to ≥64-slice CCTA facilities for correct use per NICE guidance.